4 abstracts on imetelstat at ASH2017
Posted: Thu Nov 02, 2017 11:58 am
Geron Announces Presentations at American Society of Hematology Annual Meeting
Imetelstat Clinical Data from Part 1 of IMerge in Myelodysplastic Syndromes to be Presented
MENLO PARK, Calif., Nov. 01, 2017 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq:GERN) today announced that four abstracts related to the telomerase inhibitor imetelstat have been accepted for presentation at the 59th American Society of Hematology (ASH) Annual Meeting and Exposition to be held in Atlanta, Georgia from December 9-12, 2017. The abstracts were published today on the ASH website at www.hematology.org.
Clinical Data Presentation
An abstract containing data from the first 32 patients enrolled in Part 1 of IMerge, the ongoing Phase 2/3 clinical trial of imetelstat in patients with lower risk myelodysplastic syndromes (MDS) being conducted by Janssen Research & Development, LLC., was accepted for a poster presentation.
Title: Efficacy and Safety of Imetelstat in RBC Transfusion-Dependent (TD) IPSS Low/Int-1 MDS Relapsed/Refractory to Erythropoiesis-Stimulating Agents (ESA) (IMerge) (Abstract #4256)
Date: Monday, December 11, 2017
Time: 6:00 p.m. – 8:00 p.m. ET
Pre-Clinical Data Presentations
Three abstracts by academic collaborators were selected for presentation that build on previous studies investigating imetelstat’s effects and mechanism of action in pre-clinical models of hematologic myeloid malignancies.
Title: Imetelstat, a Telomerase Inhibitor, Is Capable of Depleting Myelofibrosis Hematopoietic Stem Cells and Progenitor Cells (Abstract #1654)
Date: Saturday, December 9, 2017
Time: 5:30 p.m. - 7:30 p.m. ET
Title: Telomerase Inhibition Impairs Self-Renewal of b-Catenin Activated Myeloproliferative Neoplasm Progenitors (Abstract #2860)
Date: Sunday, December 10, 2017
Time: 6:00 p.m. – 8:00 p.m. ET
Title: Integrated Molecular Analysis Identifies Replicative Stress as Sensitizer to Imetelstat Therapy in AML (Abstract #798)
Date: Monday, December 11, 2017
Time: 5:45 p.m. ET
link: http://ir.geron.com/phoenix.zhtml?c=673 ... ID=2313299
Imetelstat Clinical Data from Part 1 of IMerge in Myelodysplastic Syndromes to be Presented
MENLO PARK, Calif., Nov. 01, 2017 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq:GERN) today announced that four abstracts related to the telomerase inhibitor imetelstat have been accepted for presentation at the 59th American Society of Hematology (ASH) Annual Meeting and Exposition to be held in Atlanta, Georgia from December 9-12, 2017. The abstracts were published today on the ASH website at www.hematology.org.
Clinical Data Presentation
An abstract containing data from the first 32 patients enrolled in Part 1 of IMerge, the ongoing Phase 2/3 clinical trial of imetelstat in patients with lower risk myelodysplastic syndromes (MDS) being conducted by Janssen Research & Development, LLC., was accepted for a poster presentation.
Title: Efficacy and Safety of Imetelstat in RBC Transfusion-Dependent (TD) IPSS Low/Int-1 MDS Relapsed/Refractory to Erythropoiesis-Stimulating Agents (ESA) (IMerge) (Abstract #4256)
Date: Monday, December 11, 2017
Time: 6:00 p.m. – 8:00 p.m. ET
Pre-Clinical Data Presentations
Three abstracts by academic collaborators were selected for presentation that build on previous studies investigating imetelstat’s effects and mechanism of action in pre-clinical models of hematologic myeloid malignancies.
Title: Imetelstat, a Telomerase Inhibitor, Is Capable of Depleting Myelofibrosis Hematopoietic Stem Cells and Progenitor Cells (Abstract #1654)
Date: Saturday, December 9, 2017
Time: 5:30 p.m. - 7:30 p.m. ET
Title: Telomerase Inhibition Impairs Self-Renewal of b-Catenin Activated Myeloproliferative Neoplasm Progenitors (Abstract #2860)
Date: Sunday, December 10, 2017
Time: 6:00 p.m. – 8:00 p.m. ET
Title: Integrated Molecular Analysis Identifies Replicative Stress as Sensitizer to Imetelstat Therapy in AML (Abstract #798)
Date: Monday, December 11, 2017
Time: 5:45 p.m. ET
link: http://ir.geron.com/phoenix.zhtml?c=673 ... ID=2313299